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§Keld Fosgerau and Torsten Hoffmann
Zealand Pharma A/S, Smedeland 36, Glostrup, 2600 Copenhagen, Denmark
Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe
and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research
and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in
clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been
picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples
of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.
Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging
new opportunities in peptide drug design and development.Introduction
More than 7000 naturally occurring peptides have been identified,
and these often have crucial roles in human physiology, including
actions as hormones, neurotransmitters, growth factors, ion chan-
nel ligands, or anti-infectives [1–4]. In general, peptides are selec-
tive and efficacious signaling molecules that bind to specific cell
surface receptors, such as G protein-coupled receptors (GPCRs) or
ion channels, where they trigger intracellular effects. Given their
attractive pharmacological profile and intrinsic properties, pep-
tides represent an excellent starting point for the design of novel
therapeutics and their specificity has been seen to translate into
excellent safety, tolerability, and efficacy profiles in humans. This
aspect might also be the primary differentiating factor of peptides
compared with traditional small molecules. Furthermore, peptide
therapeutics are typically associated with lower production com-
plexity compared with protein-based biopharmaceuticals and,
therefore, the production costs are also lower, generally approach-
ing those of small molecules. Thus, in several ways, peptides are in
the sweet spot between small molecules and biopharmaceuticals.
Naturally occurring peptides are often not directly suitable for use
as convenient therapeutics because they have intrinsic weaknesses,§ This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which
permits non-commercial use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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122 www.drugdiscoverytoday.com 1359-6446/06/$ - see front matter  20including poor chemical and physical stability, and a short circulating
plasma half-life. These aspects must be addressed for their use as
medicines. Some of these weaknesses have been successfully resolved
through what we term the ‘traditional design’ of therapeutic peptides
as described below (see Fig. 1 for a full SWOT analysis of peptides as
therapeutics). Besides traditional peptide design, a range of peptide
technologies has been emerging that represent the opportunities and
future directions within the peptide field. These include multifunc-
tional and cell penetrating peptides, as well as peptide drug conjugates
and technologies focusing on alternative routes of administration.
Here, we present a chain of thoughts leading to the conclusion that
peptides offer enormous growth potential as future therapeutics.
Peptide drug market
During the past decade, peptides have gained a wide range of
applications in medicine and biotechnology, and therapeutic
peptide research is also currently experiencing a renaissance for
commercial reasons. For example, the peptide-based medicine
LupronTM from Abbott Laboratories for the treatment of prostate
cancer and more, achieved global sales of more than US$2.3 billion
in 2011 [5]. In addition, LantusTM from Sanofi (which is really at
the border between a peptide drug and a small biopharmaceutical)
reached sales of US$7.9 billion in 2013. Currently, there are more
than 60 US Food and Drug Administration (FDA)-approved pep-
tide medicines on the market and this is expected to grow signifi-
cantly, with approximately 140 peptide drugs currently in clinical
trials and more than 500 therapeutic peptides in preclinical14 The Authors. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/
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Strengths
• Good efficacy, safety, and tolerability
• High selectivity and potency
• Predictable metabolism
• Shorter time to market
• Lower attrition rates
• Standard synthetic protocols
Opportunities
• Discovery of new peptides,
including protein fragmentation
• Focused libaries and optimized
designed sequences
• Formulation development
• Alternative delivery routes besides
parental
• Multifunctional peptides and
conjugates
Weaknesses
• Chemically and physically instable
• Prone to hydrolysis and oxidation
• Tendency for aggregation
• Short half-life and fast elimination
• Usually not orally available
• Low membrane permeability
W
TO Threats
• Immunogenicity
• New advancements in genomics,
proteonimics, and personalized
medicine
• Significant number of patent expiries
• Price and reimbursement
environment
• Increasing safety and efficacy
requirements for novel drugs
S
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FIGURE 1
Analysis of the strengths, weaknesses, opportunities, and threats (SWOT) of naturally occurring peptides in their use as therapeutics as seen from our point of view.
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Ndevelopment. An overview was presented in a recent review by
Kaspar and Reichert [5].
In terms of value, the global peptide drug market has been
predicted to increase from US$14.1 billion in 2011 to an estimated
US$25.4 billion in 2018, with an underlying increase in novel
innovative peptide drugs from US$8.6 billion in 2011 (60%) to
US$17.0 billion (66%) in 2018 [6]. The most recent example of a
novel peptide drug class is the group of glucagon-like peptide-1
(GLP-1) agonists for the treatment of type 2 diabetes mellitus
(T2DM), which reached total sales of over US$2.6 billion in 2013,
with VictozaTM, the most prominent member of the class, reaching
blockbuster status. A status of the top-selling peptide therapeutics
was given in a recent report from Transparency Market Research [6].
The main disease areas currently driving the therapeutic use of
peptide drugs are metabolic diseases and oncology. The former can
be characterized by the epidemic growth in both obesity and
T2DM, the latter by a rising mortality and need for chemotherapy
replacement, as well as cancer supportive care. The use of peptide
therapeutics in the treatment of diabetes and obesity is probably
why North America currently represents the largest share of the
peptide drug market, with the Asian market expected to have the
largest growth. The movement of the pharmaceutical industry
into rare diseases and orphan drugs has also been extended to
peptides, and marketed examples in this area include teduglutide,
a GLP-2 receptor 2 agonist for short bowel syndrome, and pasir-
eotide, a somatostatin receptor agonist for the treatment of Cush-
ing’s syndrome. Moreover, there seems to be a current trend
towards the disease areas of infectious diseases and inflammation,
where several peptides are undergoing clinical testing.
Currently, most peptide drugs are administered by the parental
route and approximately 75% are given as injectables. However,
alternative administration forms are gaining increasing traction,including oral, intranasal, and transdermal delivery routes,
according to the respective technology developments [6]. One
example of an alternative administration route evaluated for
application to peptides is the transbuccal delivery via the combi-
nation of gold nanoparticles (Midatech) and the PharmFilmTM
(Monosol Rx) technology. Accordingly, Midasol Therapeutics is
currently carrying out clinical development of a transbuccal de-
livery system that utilizes insulin-passivated gold glyconanopar-
ticles [7]. Another example is the TopActTM technology platform
from ActoGeniX, which might enable oral delivery of peptides
directly expressed in the gastrointestinal tract [8].
The use of alternative administration forms could also enable
greater usage of peptide therapeutics in other disease areas, such as
inflammation, where topical administration of peptides could be
the basis for highly efficacious novel treatments. Although not
within the scope of this article, peptides are often excellent bio-
markers and, therefore, can also be used for diagnostic purposes
[9]. Finally, peptides have also found an application as vaccines.
Traditional peptide technologies
Peptides have evolved as highly potent signal transduction mole-
cules, exerting powerful physiological effects. As illustrated in our
SWOT analysis (Fig. 1), they are generally characterized by a
relatively short circulating plasma half-life, as well as suboptimal
physical and chemical properties for their use as medicines. Con-
sequently, traditional rational design of peptide therapeutics has
focused on techniques to mitigate these weaknesses, as outlined in
Fig. 2.
Rational design of peptide therapeutics
Rational design can start with a known crystal structure of the
peptide giving the secondary and tertiary structure. Then, viawww.drugdiscoverytoday.com 123
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FIGURE 2
The traditional structure-based design strategies that are used in peptide drug discovery. This includes substitution of amino acids (AA), and the building of
structure–activity relations (SAR) via elements such as an alanine (Ala) scan and estimation of EC50 (half maximal effective concentration).
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scan), and small focused libraries, the structure–activity relation
(SAR) is built in sequential steps that lead to the identification of
essential amino acids and also sites for possible substitution. In
this process, and especially when liquid drug formulations are the
desired final product, it is an important step to identify amino
acids that are chemically labile and prone to events such as
isomerization, glycosylation, or oxidation, which should be
avoided [10].
Another important aspect in rational peptide drug design is to
improve the physicochemical properties of natural peptides,
which often have a tendency to aggregate and are sometimes
poorly water soluble [11]. Chemical design strategies to avoid
aggregation include the corruption of hydrophobic patches,
which can be achieved by means of substitutions or N-methylation
of particular amino acids. If solubility issues exist for a certain
peptide drug candidate, the common focus area is on charge
distribution and the isoelectric point (pI) of the peptide, in relation
to the pH of the desired formulation of the final product.
The physicochemical properties of peptides can also be im-
proved by the introduction of stabilizing a-helixes, salt bridge
formations, or other chemical modifications, such as lactam
bridges. Modifications introduced via rational design to improve
the physicochemical properties of a given peptide must match the
overall desired pharmacological and pharmacokinetic properties
of the peptide therapeutic. The use of predictive IT software tools
for the facilitation of such rational peptide design is expected to
increase in the future as these tools become increasingly user
friendly.
The challenges that the intrinsic physicochemical properties
of peptides represent for their use as medicines have, in some
cases, led to suboptimal solutions for patients and physicians.124 www.drugdiscoverytoday.comAn example is the therapeutic use of glucagon for the treatment
of severe hypoglycemia in diabetes. Currently, the only marketed
glucagon rescue kit for the treatment of unconscious, hypoglyce-
mic patients, contains a lyophilized peptide powder in a sterile vial
that needs to be carefully reconstituted by gentle agitation 30
times before it can be administered subcutaneously to the uncon-
scious patient. This is a cumbersome process in what is already a
stressful situation (http://www.humalog.com/Pages/glucagon-
severe-low-blood-sugar.aspx).
There is a general notion that second-generation  peptide
medicines optimized for therapeutic use via rational design will
lead to more user-friendly products. An example of such an
approach is the invention and design of a glucagon analog that
is stable in a liquid dosage form and suitable for application as a
ready-to-use rescue pen [12]. Furthermore, such products can be
used as part of a closed-loop dual chamber artificial pancreatic
device that can deliver both insulin and glucagon, where the
therapeutics would be centrally released by an automatic pump
and coupled to a continuous blood glucose sensor. With the
rapid development and further miniaturization of devices,
pumps, and IT controlled sensor feedback systems, it is envisaged
that pulsatile delivery systems could be developed that would
enable smart delivery of peptides. These medicines might apply
and mimic the rapid on- and off-set of natural peptides, as in the
glucagon example above.
Approaches for plasma half-life extension
In general, natural peptides have a relatively short circulating
plasma half-life and, thus, several techniques for half-life exten-
sion have been developed. A first-line approach is to limit the
enzymatic degradation of the peptide through identification of
possible molecular cleavage sites followed by substitution of
Drug Discovery Today  Volume 20, Number 1  January 2015 REVIEWS
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cleavage can also be obtained through enhancement of the sec-
ondary structure of the peptides (i.e. folding). This approach
includes insertion of a structure inducing probe (SIP)-tail, lactam
bridges, and stapling or cliping of peptide sequences, or by cycli-
zation [13–16]. Biotechnology companies working in this research
field include Pepscan and Aileron Therapeutics.
Several strategies use binding to the circulating protein albumin
as a vehicle to obtain half-life extensions that lead to peptide
therapeutics that have to be administered less frequently, in some
cases up to once weekly. These strategies include peptide acylation
(as seen in the GLP-1 agonist Victoza [17]), insertion of albumin-
binding peptide elements in the peptide backbone, or conjugation
to albumin-binding antibody fragments (AlbudAbTM technology,
[18]). Polyethylene glycol (PEG)-ylation has been used to limit
globular filtration and thereby increasing plasma half-life by
limiting the elimination of peptides [19]. However, because of
increased safety and tolerability concerns relating to the use of
PEG as a component of an injectable therapeutic, PEGylation has
become a less preferred choice (http://www.ema.europa.eu/docs/
en_GB/document_library/Scientific_guideline/2012/11/WC
500135123.pdf). Finally, much can be achieved in terms of extend-
ing the plasma half-life of a peptide (and also its chemical stability)
by means of formulations. Recently, an ingenious formulation
approach was developed by Intarcia [20] using an implantable
device that delivers peptide therapeutics from a dry reservoir for
up to 1 year through an osmotic pump mechanism. This innovative
approach opens an entirely new avenue for the delivery of peptides
as medicines, addressing patient convenience and compliance
through the successful design of a most-elegant delivery solution.
Before the Intarcia solution, another earlier example of such an
approach is the leuprolide acetate implant (ViadurTM) for the pallia-
tive treatment of advanced prostate cancer.TABLE 1
GLP-1 agonists currently in clinical or preclinical testinga
Company Peptide name Devel
Lilly Cpd86 Preclin
Zealand Pharma ZPGG-72 Preclin
ZP3022 Preclin
Prolor (Opko Biologics) MOD-6030 Preclin
Zealand Pharma ZP2929 Phase
Hamni Pharmaceuticals HM12525A Phase
Diartis Pharmaceuticals VSR859 Phase
Novo Nordisk NN9926 Phase
TransTech Parma TTP273/TTP054 Phase
Zydus-Cadila ZYOG1 Phase
Roche MAR709 Phase
Eli Lilly TT401 Phase
Hamni Pharmaceuticals HM11260C Phase
PhaseBio Pharmaceuticals PB1023 Phase
Eli Lilly Dulaglutide Phase
Novo Nordisk Semaglutide Phase
Intarcia ITCA Phase
a Abbreviation: SC subcutaneous.Emerging peptide areas and technologies
There is a large pool of natural peptides, some of which represent
excellent starting points for therapeutics. In the metabolic area, for
example the gut, the microbiome has received much interest
because it is rich in diverse bacteria that could give rise to the
identification of new peptides from protein fragments, degrada-
tion products, or signaling molecules [21]. We are convinced that
ongoing microbiome research will help to enrich significantly the
opportunities for peptide therapeutics in metabolic diseases.
However, for innovative peptide drug development, chemists
must look beyond traditional peptide technologies. Among the
emerging technologies in the field are multifunctional peptides
representing more than one pharmacological activity, such as dual
or even triple agonism. This approach makes sense based on
information from genomics. Thus, it is evident that knockout
animals, where only a single gene is deleted, often present with
no distinct phenotype. Also, despite broad industrial efforts in the
GPCR field that have led to the successful identification of several
selective agonists and antagonists in clinical development, only a
few ligands resulted in approved medicines. These lessons point to
the redundancy in biological systems and favor multitarget
approaches for the development of medicines. Another aspect
of applying a polypharmacology approach is the possibility of
more individualized and personalized treatment of differentiated
patient groups.
Current multifunctional peptides in development include an-
timicrobial peptide drug candidates that have additional biologi-
cal functions, such as immune stimulation and wound healing.
Also, the trend towards multifunctional peptides can be seen in
the GLP-1 agonist field, which represents an established drug class
with several products, including ByettaTM (exenatide), Bydur-
eonTM (exenatide), VictozaTM (liraglutide), LyxumiaTM (lixisena-
tide), and most recently TanzeumTM (albiglutide), beingopment stage Target Dosing regimen
ical GLP-1/GIP SC, once daily
ical GLP-1/GLP-2 SC, once daily
ical GLP-1/CCKB SC, once daily
ical GLP-1/GCG SC, once weekly
 I GLP-1/GCG SC, once daily
 I GLP-1/GCG SC, once weekly
 I GLP-1 SC, once monthly
 I GLP-1 Oral, long acting
 II GLP-1 Oral
 I GLP-1 Oral
 II GLP-1/GIP SC, once daily
 II GLP-1/GCG SC, once weekly
 II GLP-1 SC, once weekly
 II GLP-1 SC, once weekly
 III GLP-1 SC, once weekly
 III GLP-1 SC, once weekly
 III GLP-1 SC, once yearly
www.drugdiscoverytoday.com 125
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across clinical and preclinical pipelines, it is evident that several
companies have focused on the development of GLP-1 dual and
even triple agonists for a more diversified and personalized treat-
ment of T2DM and/or obesity (Table 1). It is also evident from
Table 1 that, in addition to multifunctional peptides, there is a
focus on improved patient convenience and compliance and,
therefore, strategies towards less-frequent dosing, or even oral
administration of GLP-based drugs, being pursued in clinical
development.
Examples of other peptide compounds or modules that have
been combined with GLP-1 agonism include glucagon (GCG)
[22,23], glucose-dependent insulinotropic peptide (GIP) [24], cho-
lecystokinin B (CCKB) [25], and glucagon-like peptide 2 (GLP-2)
[26]. The most clinically advanced multifunctional peptides are
GLP-1–GIP and GLP-1–GCG dual agonists, which are currently
being investigated in clinical proof-of-concept studies in patients
who are overweight and have diabetes. The GLP-1–GCG dual
agonists (some of which are modulated over the natural dual-
acting gut peptide oxyntomodulin) are expected to provide a
greater weight loss in overweight patients with T2DM compared
with a pure GLP-1 agonist, via a GCG-derived increase in energy
expenditure [27]. Another example is the GLP-1–CCKB dual ago-
nists [25] where the addition of CCKB (gastrin) agonism to the
GLP-1 action is expected to enhance the pancreatic b cell function,
which in turn might aid in minimizing or preventing disease
progression in T2DM. These examples illustrate how the addition
of a second activity to the established effects of GLP-1 could lead to
more individualized medical solutions with increased efficacy
(Fig. 3).
Chemical strategies for the design of multifunctional peptides
can include a hybrid of two peptides being bound together like
modules either directly or via a linker, or chimeras where the
second pharmacological activity is ‘designed in’ to an existing
peptide backbone (Fig. 3). Most recently, GLP-1–GIP–GCG tripleObesity Diabetes
GLP-1 GLP-1–CCKBGLP-1–GCG
Chimera Hybrid
GLP-1–GIP
GLP-1–GCG GLP-1 GLP-1 CCKB
GLP-1–GLP-2
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FIGURE 3
Multifunctional peptides. The figure illustrates how the diversification of GLP-
1-based peptides into multifunctional peptides could occur for fine-tuned
pharmacology towards obesity or disease prevention in type 2 diabetes
mellitus. These multifunctional peptides could include a hybrid of two
peptides being bound together like modules either directly or via a linker, or
chimeras where the second pharmacological activity is ‘designed in’ to an
existing peptide backbone. Abbreviations: CCKB, cholecystokinin B; GCG,
glucagon; GIP, glucose-dependent insulinotropic peptide; GLP-1/2, glucagon-
like peptide 1/2.
126 www.drugdiscoverytoday.comincretin agonists have been described in the patent literature as
potent antidiabetic and antiobesity agents, having shown strong,
beneficial effects in rodents [28,29], and even peptides acting on
four different receptors (quadruples) are, in our experience, chem-
ically feasible, but have not yet emerged in the public domain.
The development of multifunctional peptides could present a
challenge in the sense that the prediction of the in vivo outcome for
the drug candidates is more complex with dual target pharmacol-
ogy versus single target pharmacology. One challenging aspect of
the translation from in vitro to in vivo effects is the potential biased
signaling that might arise from novel ligands aimed at two or more
receptors [30]. In addition, the translation of results from animal
models to human situations might be associated with greater risk
for multifunctional peptides compared with single receptor pep-
tides, because the uncertainty from two or more targets is multi-
plied. In the antibody field, similar challenges have been observed
in the development of bispecific antibodies for the treatment of
cancer. For these reasons, it is relevant to expect that multifunc-
tional peptides might arise mainly from established paradigms, as
observed in the GLP-1 field, more than from completely novel
peptide combinations.
Most peptide therapeutics are injectables and there are only a
few oral peptide drugs in existence, cyclosporine (NeoralTM) and
desmopressin (MinirinTM) being prominent examples. However, it
is expected that the market will see an increase in orally bioavail-
able peptides in development because they offer greater conve-
nience for patients. The challenges relating to development of oral
peptides include acidic and enzymatic degradation of the mole-
cules in both the gastrointestinal tract, and when crossing the
intestinal mucosa via either active transport or passive diffusion.
Therefore, chemical strategies in the design of peptides for oral
administration include the previously mentioned stabilizing of
the secondary structures, such as stapled peptides, building hy-
drophobic faces, cyclization, N-methylation, and establishment of
intramolecular hydrogen bonds. Various biotechnology compa-
nies are active in this field of peptide drug research, including Ra
Pharma, Peptidream, and Cyclogenix (cyclic peptides), and Bicycle
Therapeutics (phage display using chemical ligation libraries).
Formulary aspects and permeability enhancers are also impor-
tant. The question applicable to orally bioavailable peptide drugs is
whether the molecular changes introduced through the above-
mentioned derivatizations hamper the in vivo efficacy of the
therapeutics. Another point of relevant consideration in relation
to the development of orally available peptide therapeutics is to
what extent an injectable medicine is really inconvenient for
patients. New and more patient-friendly injection technologies
are constantly being developed, including smaller needles and
even more convenient devices, which should also be taken into
account in the context of the severity of the disease being treated.
It is our belief that injectable peptide medicines will remain the
preferred solution over orally administered peptides, especially for
patient populations who are already using injectables. An example
would be patients with diabetes treated with insulin.
Native peptides in general do not cross cell membranes, which
has previously limited their therapeutic use to extracellular targets.
However, over recent years, technologies have been invented
for the insertion of membrane permeability elements, including
so-called ‘cell penetrating peptides’, such as penetratin or the
Drug Discovery Today  Volume 20, Number 1  January 2015 REVIEWS
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ghauserpharma.com/wp-content/uploads/peptide-drug-conju
gates-specchem1.pdf), making it possible to reach intracellular
targets with peptides to some degree. One challenge of cell pene-
trating peptides, which is likely to be also shared by orally bio-
available peptides, is a probable loss of efficacy because usually
only a fraction of the peptide drug reaches the target. Another
important aspect to consider when developing cell penetrating
peptides is whether their molecular properties resemble those of
small molecules more, including lower specificity and, therefore,
greater safety risk because of an increased volume of distribution.
In other words, making peptides cell penetrant or orally bioavail-
able might tip the SWOT analysis (Fig. 1) towards that of a small
molecule.
Finally, we point to conjugation of peptides with, for example,
small molecules, oligoribonucleotides, or antibodies as new possi-
ble avenues to pursue the development of novel peptide thera-
peutics with improved efficacy and safety properties. In oncology,
for example, this approach has gained must interest, resulting in
more than 20 peptide conjugates being evaluated in clinical trials
(http://cedarburghauserpharma.com/wp-content/uploads/peptide-
drug-conjugates-specchem1.pdf). Although peptides in clinical
testing in the oncology area in general have experienced a
relatively high level of attrition, this conjugation principle has
been exemplified by the combination of a neurotensin 1 (NT1)
receptor peptide agonist conjugated to a radioactive ligand for
the treatment of pancreatic cancer. Via this conjugate, the
peptide component ensures targeted delivery of the radioligand
to the NT1 receptor expressed at the relevant site, enabling a
high local concentration of the chemotherapeutic agent. As a
consequence, other parts of the body are also less exposed, which
in turn is expected to result in an improved safety margin, and
potential higher and more efficacious dosing of the anticancer
agent [31]. In antibody–peptide conjugates, the antibody part
might take the role as the targeting entity, whereas the peptide is
the effector part. Pursuing the conjugation route for multifunc-
tional peptides might not only result in an attractive therapeutic
potential, but also present challenges in the form of a relatively
complex drug development path, including increased regulatory
requirements and more complex production of the pharmaco-
logically active ingredient. Biotechnology companies workingwith peptide conjugates include Angiochem and 3B Pharmaceu-
ticals, among others.
Concluding remarks
Peptides have gained increased interest as therapeutics during re-
cent years. More than 60 peptide drugs have reached the market for
the benefit of patients and several hundreds of novel therapeutic
peptides are in preclinical and clinical development. The key con-
tributor to this success is the potent and specific, yet safe, mode of
action of peptides. We believe that the future development of
peptide drugs will continue to build upon the strengths of naturally
occurring peptides, with the application of traditional rational
design to improve their weaknesses, such as their chemical and
physical properties. We also expect that emerging peptide technol-
ogies, including multifunctional peptides, cell penetrating peptides
and peptide drug conjugates, will help broaden the applicability of
peptides as therapeutics. These new peptide technologies include
alternative administration routes beyond the predominantly paren-
tal injection route and conjugates of peptides to antibodies or to
small molecules. We foresee that medicinal peptide chemistry could
be applied increasingly in a modular fashion, comparable to micro-
electronics or LEGOTM bricks. The intelligent assembly of known
modules with unique properties and functions could lead to the
construction of multifunctional molecular medicines with im-
proved efficacy, pharmacokinetic properties, and targeted delivery.
The analogy to LEGOTM bricks is a good one because the possible
combinations of amino acids into peptides are almost unlimited, for
example, a combination of any of the 20 naturally occurring amino
acids built into a 20-mer would alone give 2020 = 1.05  e26 possi-
bilities. Taking all of the above into account, we are convinced that
peptides offer enormous growth potential as future therapeutics for
the treatment of unmet medical needs.
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